Tolerability of statin-based management of patients with a history of statin-associated muscle symptoms: protocol for a systematic review. by Villoz, Fanny et al.
1Villoz F, et al. BMJ Open 2021;11:e052341. doi:10.1136/bmjopen-2021-052341
Open access 
Tolerability of statin- based management 
of patients with a history of statin- 
associated muscle symptoms: protocol 
for a systematic review
Fanny Villoz   ,1,2 Christina Lyko,1 Cinzia Del Giovane,1 Nicolas Rodondi,1,2 
Manuel R Blum1,2
To cite: Villoz F, Lyko C, Del 
Giovane C, et al.  Tolerability 
of statin- based management 
of patients with a history of 
statin- associated muscle 
symptoms: protocol for a 
systematic review. BMJ Open 
2021;11:e052341. doi:10.1136/
bmjopen-2021-052341
 ► Prepublication history and 
additional supplemental material 
for this paper are available 
online. To view these files, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2021- 052341).
Received 13 April 2021
Accepted 02 July 2021
1Institute of Primary Health Care 
(BIHAM), University of Bern, 
Bern, Switzerland
2Department of General Internal 
Medicine, Inselspital, Bern 
University Hospital, University of 
Bern, Bern, Switzerland
Correspondence to
Dr Manuel R Blum;  
 manuel. blum@ biham. unibe. ch
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Statin- associated muscle symptoms 
(SAMSs) are a major clinical issue in the primary and 
secondary prevention of cardiovascular events. Current 
guidelines advise various approaches mainly based on 
expert opinion. We will lead a systematic review and 
meta- analysis to explore the tolerability and acceptability 
and effectiveness of statin- based therapy management 
of patients with a history of SAMS. We aim to provide 
evidence on the tolerability and different strategies of 
statin- based management of patients with a history of 
SAMS.
Methods and analysis We will conduct a systematic 
review of randomised controlled trials (RCTs) and non- 
randomised studies with a control group. We will search 
in Data sources MEDLINE, EMBASE, Cochrane Central 
Register of Controlled Clinical Trials, Scopus,  Clinicaltrials. 
gov and Proquest from inception until April 2021. Two 
independent reviewers will carry out the study selection 
based on eligibility criteria. We will extract data following 
a standard data collection form. The reviewers will use 
the Cochrane Collaboration’s tools and Newcastle- Ottawa 
Scale to appraise the study risk of bias. Our primary 
outcome will be tolerability and our secondary outcomes 
will be acceptability and effectiveness. We will conduct 
a qualitative analysis of all included studies. In addition, 
if sufficient and homogeneous data are available, we 
will conduct quantitative analysis. We will synthesise 
dichotomous data using OR with 95% CI and continuous 
outcomes by using mean difference or standardised mean 
difference (with 95% CI). We will determine heterogeneity 
visually with forest plots and quantitatively with I2 and Q- 
test. We will summarise the confidence in the quantitative 
estimate by using Grading of Recommendations 
Assessment, Development and Evaluation approach.
Ethics and dissemination As a systematic review of 
literature without collection of new clinical data, there 
will be no requirement for ethical approval. We will 
disseminate findings through peer- reviewed publications.
PROSPERO registration number CRD42020202619.
INTRODUCTION
Statin- associated muscle symptoms (SAMSs), 
a composite of muscle symptoms appearing 
consequent to the initiation or the increase 
of a statin’s treatment,1 are a major clinical 
issue in the primary and secondary preven-
tion of cardiovascular events. Statins are a 
cornerstone in the prevention of cardiovas-
cular risk and mortality,2 3 and are widely 
prescribed with increased intensity to achieve 
currently recommended low- density lipopro-
tein cholesterol (LDL- C) levels.4–6 Neverthe-
less, SAMS, a commonly reported muscle 
symptom, threatens the ability of a significant 
proportion of patients to tolerate evidence- 
based dosing: based on observational data or 
registries reported by patients. SAMS affects 
between 5% and 29% of statin- treated indi-
viduals.1 This lack of tolerability is associ-
ated with higher cardiovascular disease risk.6 
Meanwhile, the high cost of the non- statin 
alternative drugs, such as PCSK9 inhibitors, 
and the lack of other effective alternatives, 
remains a concern,7 8 and statins currently 
remain the main treatment option.
The European Atherosclerosis Society 
Consensus Panel Statement recommend 
multiple different strategies to manage 
patients with SAMS but they are based only on 
experts’ opinion due to lack of sufficient data.1 
Strengths and limitations of this study
 ► This systematic review protocol observes the 
Preferred Reporting Items for Systematic Review 
and Meta- Analyses Protocols checklist.
 ► This systematic review will be the first to systemati-
cally review tolerability of statin- based management 
in patients with a history of statin- associated mus-
cle symptom.
 ► This systematic review will provide the highest lev-
el of evidence for clinical decisiveness due to the 
inclusion of randomised controlled trials (RCTs) as 
well as non- RCTs.















pen: first published as 10.1136/bm


















pen: first published as 10.1136/bm


















pen: first published as 10.1136/bm


















pen: first published as 10.1136/bm


















pen: first published as 10.1136/bm


















pen: first published as 10.1136/bm


















pen: first published as 10.1136/bm





2 Villoz F, et al. BMJ Open 2021;11:e052341. doi:10.1136/bmjopen-2021-052341
Open access 
A systematic review and meta- analysis of 12 randomised 
controlled trials (RCTs) and one quasi- RCT on the effi-
cacy and safety of alternate day versus daily dosing of 
statins with participants without previous SAMS in 2017 
found a statistically non- significant difference in terms 
of change in LDL- C in both groups and concluded good 
adherence and tolerability of both treatment.9 However, 
this meta- analysis has not assessed the specific population 
of patients suffering from SAMS. A systematic review of 
three case reports, five retrospective studies, one prospec-
tive study and one randomised trial assessing effectiveness 
of intermittent non- daily administration of statin strate-
gies with patients with previous statin- induced myopathy 
in 2013 found that 70% of patients could tolerate an 
intermittent dosing strategy and concluded that uncer-
tainty remains and that larger scale randomised trials are 
required.10
Since publication of these systematic reviews, new 
evidence on the management of SAMS has emerged both 
from RCTs and observational data.11–16 Therefore, we 
decided to conduct a systematic review and meta- analysis 
to investigate the tolerability, acceptability and effective-
ness of statin- based therapy management in patients with 
a history of SAMS compared with all available compar-
ators. In a patient- centred perspective, we will focus on 
the tolerability as the primary outcome. We will not only 
include intermittent dosing strategies, but also other 
strategies to broaden our conclusion. Our systematic 
review and meta- analysis will be complementary to the 
ongoing meta- analysis17 on statin adverse events with the 
particularity to focus on patients with a history of SAMS 
and SAMS’ management.
We aim to provide quality evidence for the tolerability 
of statin- based management of patients with a history of 





We will include human RCTs and prospective and retro-
spective cohort studies with a control group, published 
in English from inception until April 2021. There will be 
no follow- up length or setting restriction. We will include 
relevant studies mainly based on the population and 
intervention criteria to avoid exclusion of studies which 
poorly report tolerability or adverse outcomes in their 
titles and abstracts. In the case of multiple publications 
from the same study, we will include the report with the 
most relevant data relating to our interest.
We will differentiate between the absence of muscle 
symptoms and the absence of reporting muscle symp-
toms and include data only from studies reporting the 
absence of muscle symptoms. We will include post- hoc 
analysis of prior RCT so long as there is a comparison 
group.
Types of participants
We will include studies examining adult humans previ-
ously on statins with a history of SAMS. We will also 
include studies examining adults previously on statins 
with a history of statin intolerance without precision of 
SAMS or other intolerance. Indeed, SAMS is a type of 
statin intolerance concerning specifically muscle symp-
toms. Nevertheless, some participants can also report 
other types of intolerance, as for example, impaired 
cognition,18 hepatic dysfunction19 or depression.20 SAMS 
is also a recent definition and could have been reported 
as ‘intolerance’ or ‘muscle- related adverse events’ in the 
past.
We will exclude studies examining adults without a 
history of statin intolerance, children, adolescents and 
pregnant women.
Types of interventions
We defined statin- based therapy management of patients 
with a history of SAMS as all statin management strate-
gies with the aim of optimal lipid profile lowering and 
decreasing adverse effects. Examples include statin 
continuation, re- challenge, up- titration, down- titration, 
second statin at the usual or starting dose, low dosing 
of a high- intensity statin, intermittent dosing statin. All 
the variations of statin management strategies will be 
included, for example the variation in dosage, intensity, 
frequency of delivery, duration of delivery and timing of 
delivery. All co- lifestyle modifications (exercise and diet) 
and all additional interventions in the intervention group 
are included if present in the control group too.
Types of comparators
Placebo, usual care, other statins regimens, other non- 
statin lipid- lowering drug regimens (ezetimibe, PCSK9 
inhibitors), statin regimens with additional interven-
tions (statins with ezetimibe, CoQ10, vitamin D) or no 
treatment.
Types of outcomes
Tolerability, as defined in individual studies, will be our 
main outcome. We anticipate that the proportion of 
population with muscle symptoms- related adverse events 
compared with control group would be the most feasible 
measure to analyse. If reported, we will collect time until 
muscle symptoms- related adverse events and measure the 
adverse event rate.
We defined adverse event as ‘an unfavorable outcome 
that occurs during or after the use of a drug or other 
intervention and the causal relation between the inter-
vention and the event is at least a reasonable possibility’ 
as defined in the Cochrane handbook for systematic reviews of 
interventions.21
Acceptability, as defined in individual studies, will be a 
secondary outcome. We anticipate that the proportion of 
population with muscle symptoms- related study or treat-
ment discontinuation compared with control group will 
be the most feasible measure to analyse.
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Effectiveness, defined as the change in lipid profile will 
be a secondary outcome. The lipid profile includes at 
least LDL- C in addition to total cholesterol, high- density 
lipoprotein cholesterol (HDL- C) and triglycerides as 
provided by the individual studies.
Search strategy and study selection
Search strategy
The first author will develop a search strategy for each 
database included MEDLINE, EMBASE and Cochrane 
Central Register of Controlled Clinical Trials in cooper-
ation with a trained librarian using computerised search 
(see online supplemental file 1). Search terms and syntax 
will be adapted for each specific database. Moreover, we 
will complete a hand search using forward and backwards 
citations, and evaluate the grey literature (Scopus,  Clini-
caltrials. gov and Proquest) for additional potentially rele-
vant and unpublished articles. We will search only studies 
written in English.
Study selection
Two trained reviewers (FV and CL) will evaluate indepen-
dent eligibility based on titles and abstracts of all studies 
retrieved in our electronic search.21 We will upload the 
literature search results to Rayyan QCRI, an internet- 
based software programme that facilitates collaboration 
among reviewers during the selection process. We will 
remove duplicates using reference management software. 
The two reviewers will assess the remaining studies for 
inclusion after full- text evaluation. If studies do not report 
muscle symptoms events or discontinuation in the full 
text, we will request them from the authors. We will then 
include or exclude the study, depending on the informa-
tion provided. We will still include studies with absence 
of reporting muscles symptoms if they present data of 
interest for secondary outcomes. We will include post- hoc 
analysis of prior RCT so long as there is a comparison 
group.
We will list excluded full- text studies together with the 
reason for exclusion. We will resolve discrepancies by 
making a consensus among the study team. If we cannot 
reach consensus, we will consult a third reviewer. We 
will follow the Preferred Reporting Items for System-
atic Review and Meta- Analyses recommendations to 
summarise the study selection. We will document all deci-
sions made in the study selection process.
Data extraction and management
We will manage data with an online shared data form 
among the review team.
We will use a standard data collection form, piloted by 
the review team using representative sample of included 
studies. Two reviewers will manage data in duplicate. We 
will request additional data from the authors by email. 
The two reviewers will discuss and resolve disagreements 
by consensus or consult a third reviewer.
The data collection items are listed in table 1.
Quality assessment
Two reviewers will autonomously evaluate the risk of bias 
of each study. We will use the Cochrane Collaboration 
tools for appraising the risk of bias of prospective studies 
and the Newcastle- Ottawa scale for the retrospective 
Table 1 Data collection items
General  ► Authors, journal, year of publication, title of the article.
Method  ► Study design.
 ► Participants.
 ► Sample size, loss to follow- up.
 ► Characteristics of participants at baseline as age, sex, body mass index, cardiovascular comorbidities, 
cardiovascular risk factors, co- medications with influence on the cytochrome of interest, history of adverse 




 ► Statins, doses, timing, frequency, length of intervention, washout period, duration of follow- up.
 ► Description of co- interventions, lifestyle modification, modification of baseline medication regimen.
 ► Types of comparator, doses, timing, frequency, intervention protocols, length of intervention, washout period, 
duration of follow- up.
Outcomes  ► Proportion of population with/without muscles symptoms- related adverse events, time to muscles symptoms- 
related adverse events, proportion of population with muscles symptoms related drop out, lipid profile, creatine 
kinase level, liver function test.
 ► Multiple adverse events occurrence in the same individuals.
 ► All other adverse outcomes and collection systematic: definition of each adverse outcome addressed, method 
of ascertainment (patient report vs active search), method of measurement, timing and frequency of adverse 
events, measurement of the severity.
 ► Associated factor to the adverse events.
 ► For each outcome at each time point: number of participants randomly assigned and included in the analysis; 
number of participants who withdrew, were lost to follow- up or were excluded with reasons for each.
Notes  ► Conflicts of interest, funding sources.
SAMS, statin- associated muscle symptom.
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studies. Discrepancy among the two reviewers will be 
solved by consensus or by a third person.
On the meta- bias level, a sensitivity analysis to deter-
mine the effect of selective reporting will also be consid-
ered. If data permits, we will assess small study effect via 
funnel plots and formally with the Egger test.
Data synthesis and statistical analyses
We will synthesise the systematic review qualitatively and 
quantitatively.
In the qualitative synthesis, we will summarise the char-
acteristics and findings of the included studies in text 
and tables. We will categorise our summaries of studies 
according to type of intervention, comparator, outcome 
and study design. We will present the limitations of 
the included studies and recommendations for future 
research.
In the quantitative synthesis, we will perform study level 
meta- analysis if studies are sufficiently homogenous and if 
enough data are available.
We will use the same summary measures in RCT and 
non- randomised trials. For tolerability and acceptability, 
we will synthesise dichotomous data using OR with 95% 
CI. For efficacy, we will synthesise the change in lipid 
profile from baseline as a continuous outcome using 
mean difference or standardised mean difference (with 
95% CI) depending on the different metrics.
When studies reported the number of muscle events 
instead of the number of subjects experiencing muscular 
event, we will contact the authors to request the number 
of patients with >0 events. If this could not be addressed, 
we will make the assumption of one event per subject. If 
a group of the studies reported zeroes event, we will use 
the zero count- cell method to allow statistical measures. 
We will exclude studies with zero events in both groups 
from the analysis.
Concerning acceptability, if the measure to analyse is the 
proportion of population with muscle symptoms- related 
discontinuation compared with the control group, we will 
assess if the participant was still blinded to treatment attri-
bution before the discontinuation to avoid bias.
Regarding the variety of study designs, we will first pool 
data, then analyse data from different type of studies sepa-
rately (eg, RCT vs non- randomised control studies, cross-
over trial vs parallel trial). We will collect the variables 
used for the adjustment in each study. When dealing with 
crossover trials, data after the crossover will be analysed.
We will assess heterogeneity visually with forest plots, I² 
test and the Q- test. We will assess and interpret heteroge-
neity in line with the guidance in the Cochrane handbook 
of systematic reviews and meta- analysis. In case of heteroge-
neity, we will explore potential sources in subgroup anal-
yses. In the case of significant heterogeneity, we will use 
the random effect model.
We will conduct subgroup analysis to explore possible 
sources of heterogeneity: pre- planned variables to explore 
are primary versus secondary prevention, high intensity 
versus non- high intensity statins, intermittent dosing 
versus daily dosing, patients with a history of SAMS versus 
patients with a history of statin intolerance, only statins 
intervention versus statins and additional interventions 
and participants with versus without a statin at inclusion. 
If feasible, we will consider the different follow- up times 
in a meta- regression.
We will conduct the analysis using STATA V.16 software 
(StataCorp, College Station, Texas, USA).
We will recapitulate the confidence we have in the 
resulting body of evidence using Grading of Recom-
mendations Assessment, Development and Evaluation 
working group methodology.
ETHICS AND DISSEMINATION
We plan to publish the review in a clinical journal from 
the relevant field (endocrinology, cardiology and internal 
medicine).
PATIENT AND PUBLIC INVOLVEMENT
Patients and/or the public were not involved in the 
design or conduct or reporting or dissemination plans of 
this research.
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Supplementary file 1 
PRISMA-P Checklist 2 
Section and topic Item 
No 
Checklist item Information 
reported 
Line number(s) 
ADMINISTRATIVE INFORMATION   
Title:     
 Identification 1a Identify the report as a protocol of a systematic review Yes 1-3 
 Update 1b If the protocol is for an update of a previous systematic 
review, identify as such 
NA  
Registration 2 If registered, provide the name of the registry (such as 
PROSPERO) and registration number 
Yes 45 
Authors:     
 Contact 3a Provide name, institutional affiliation, e-mail address of all 
protocol authors; provide physical mailing address of 
corresponding author 
Yes 8-15 
 Contributions 3b Describe contributions of protocol authors and identify the 
guarantor of the review 
Yes    307-311 
Amendments 4 If the protocol represents an amendment of a previously 
completed or published protocol, identify as such and list 
changes; otherwise, state plan for documenting important 
protocol amendments 
Yes  320-321 
Support:     
 Sources 5a Indicate sources of financial or other support for the review Yes 312-313 
 Sponsor 5b Provide name for the review funder and/or sponsor NA  
 Role of sponsor or 
funder 
5c Describe roles of funder(s), sponsor(s), and/or 
institution(s), if any, in developing the protocol 
NA  
INTRODUCTION   
Rationale 6 Describe the rationale for the review in the context of what 
is already known 
Yes  62-95 
Objectives 7 Provide an explicit statement of the question(s) the review 
will address with reference to participants, interventions, 
comparators, and outcomes (PICO) 
Yes 96-98 
METHODS   
Eligibility criteria 8 Specify the study characteristics (such as PICO, study 
design, setting, time frame) and report characteristics 
(such as years considered, language, publication status) to 
be used as criteria for eligibility for the review 
Yes 100-205 
Information sources 9 Describe all intended information sources (such as 
electronic databases, contact with study authors, trial 
registers or other grey literature sources) with planned 
dates of coverage 
Yes 208-214 
Search strategy 10 Present draft of search strategy to be used for at least one 
electronic database, including planned limits, such that it 




Study records:     
Data management 11a Describe the mechanism(s) that will be used to manage 
records and data throughout the review 
Yes 231-237 
Selection process 11b State the process that will be used for selecting studies 
(such as two independent reviewers) through each phase 





11c Describe planned method of extracting data from reports 
(such as piloting forms, done independently, in duplicate), 
any processes for obtaining and confirming data from 
investigators 
Yes 232-237 
Data items 12 List and define all variables for which data will be sought 
(such as PICO items, funding sources), any pre-planned 
data assumptions and simplifications 
Yes Table 1 
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13 List and define all outcomes for which data will be sought, 
including prioritization of main and additional outcomes, 
with rationale 
Yes 
191-205 and Table 
1 
Risk of bias in individual 
studies 
14 Describe anticipated methods for assessing risk of bias of 
individual studies, including whether this will be done at the 
outcome or study level, or both; state how this information 
will be used in data synthesis 
Yes 238-242 
Data synthesis 15a Describe criteria under which study data will be 
quantitatively synthesised 
Yes 257-258 
15b If data are appropriate for quantitative synthesis, describe 
planned summary measures, methods of handling data 
and methods of combining data from studies, including any 
planned exploration of consistency (such as I2, Kendall’s τ) 
Yes 259-281 
15c Describe any proposed additional analyses (such as 
sensitivity or subgroup analyses, meta-regression) 
Yes 282-287 
15d If quantitative synthesis is not appropriate, describe the 
type of summary planned 
Yes 253-256 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as 





17 Describe how the strength of the body of evidence will be 
assessed (such as GRADE) 
Yes 296-298 
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P 3 
Explanation and Elaboration (cite when available) for important clarification on the items. 4 
Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P 5 
(including checklist) is held by the PRISMA-P Group and is distributed under a Creative 6 
Commons Attribution Licence 4.0.  7 
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, 8 
PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols 9 
(PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.  10 
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Search strategy 11 
Data search strategy for embase.com 
# Searches  






'anticholesteremic':ab,kw,ti,tn OR 'antihypercholesteremic':ab,kw,ti,tn OR 'altocor':ab,kw,ti,tn OR 'atorvastatin':ab,kw,ti,tn OR 
'baycol':ab,kw,ti,tn OR 'bervastatin':ab,kw,ti,tn OR 'canef':ab,kw,ti,tn OR 'cerivastatin':ab,kw,ti,tn OR 'compactin':ab,kw,ti,tn OR 
'cranoc':ab,kw,ti,tn OR 'crestor':ab,kw,ti,tn OR 'crilvastatin':ab,kw,ti,tn OR 'dalvastatin':ab,kw,ti,tn OR 'fluindostatin':ab,kw,ti,tn 
OR 'fluvastatin':ab,kw,ti,tn OR 'glenvastatin':ab,kw,ti,tn OR 'hmg coa*':ab,kw,ti,tn OR 'hydroxymethylglutaryl*':ab,kw,ti,tn OR 
'hypochol*':ab,kw,ti,tn OR 'hypolipidemic':ab,kw,ti,tn OR 'lescol':ab,kw,ti,tn OR 'lipitor':ab,kw,ti,tn OR 'lipex':ab,kw,ti,tn OR 
'lipostat':ab,kw,ti,tn OR 'livalo':ab,kw,ti,tn OR 'locol':ab,kw,ti,tn OR 'lovostatin':ab,kw,ti,tn OR 'lochol':ab,kw,ti,tn OR 
'medostatin':ab,kw,ti,tn OR 'mevacor':ab,kw,ti,tn OR 'mevalotin':ab,kw,ti,tn OR 'mevinacor':ab,kw,ti,tn OR 
'mevinolin':ab,kw,ti,tn OR 'monacolin':ab,kw,ti,tn OR 'pitava':ab,kw,ti,tn OR 'pitavastatin':ab,kw,ti,tn OR 'pravachol':ab,kw,ti,tn 
OR 'pravasin':ab,kw,ti,tn OR 'pravastatin':ab,kw,ti,tn OR 'rosuvastatin':ab,kw,ti,tn OR 'simvastatin':ab,kw,ti,tn OR 
'zocor':ab,kw,ti,tn OR 'statin*':ab,kw,ti,tn 
#3 #1 OR #2  





(((muscl* OR muscu*) NEAR/3 (pain* OR fatigue OR intoler* OR symptom*)):ti,ab,kw) OR ((statin* NEAR/3 (induc* OR relat* 
OR associ* OR intoler* OR symptom* OR 'side effect*' OR side-effect* OR 'adverse effect*')):ti,ab,kw) OR sams:ti,ab,kw OR 
sas:ti,ab,kw OR sinam:ti,ab,kw OR myopath*:ti,ab,kw OR myalg*:ti,ab,kw OR myosit*:ti,ab,kw OR necrot*:ti,ab,kw OR 
rhabdomyo*:ti,ab,kw 
#6 #4 OR #5  
#7 #3 AND #6  
#8 
'dosage schedule comparison'/exp OR 'drug choice'/exp OR 'drug dose comparison'/exp OR 'drug dose escalation'/exp OR 
'drug dose increase'/exp OR 'drug dose intensification'/exp OR 'drug dose reduction'/exp OR 'drug dose regimen'/exp OR 'drug 
dose titration'/exp OR 'drug intermittent therapy'/exp OR 'drug megadose'/exp OR 'drug microdose'/exp OR 'drug pulse 
therapy'/exp OR 'low drug dose'/exp OR 'loading drug dose'/exp OR 'maintenance drug dose'/exp OR 'recommended drug 













(((daily OR everyday OR quotidian OR 'every other' OR 'every second' OR rotat* OR alternat* OR 'non daily' OR nondaily OR 
non-daily OR hebdomad* OR weekly OR intermit* OR escalat* OR build-up OR intensif* OR reduct* OR puls*) NEAR/3 
(therap* OR dos* OR treatment OR prescript*)):ti,ab,kw) OR reinitiation:ti,ab,kw OR challeng*:ti,ab,kw OR rechalleng*:ti,ab,kw 
OR 're challeng*':ti,ab,kw or monotherap*:ti,ab,kw 
#10 #8 OR #9  
#11 #7 AND #10  
#12 
'crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled trial':de OR 'single-blind procedure':de 
OR random*:de,ab,ti OR factorial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR placebo*:de,ab,ti 








cohort:ab,ti OR (case:ab,ti AND (control:ab,ti OR controll*:ab,ti OR comparison:ab,ti OR referent:ab,ti)) OR risk:ab,ti OR 
causation:ab,ti OR causal:ab,ti OR 'odds ratio':ab,ti OR etiol*:ab,ti OR aetiol*:ab,ti OR 'natural history':ab,ti OR predict*:ab,ti 

















#14 #12 OR #13  
#15 #11 AND #14  
Filter: https://blocks.bmi-online.nl/catalog/106 
Creator: Ket JCF and Vries R de 
Notes: PubMed drafted in 2009 from: Etiology, causation, harm; and: Natural history and prognosis. In: McKibbon KA, Eady A, Marks S. PDQ 
evidence-based principles and practice. Hamilton etc.: B.C. Decker; 1999, p. 91, 110. PubMed revised in 2015 by adding '[ot]'. Embase.com drafted 
by De Vries, 2015. PubMed and Embase.com for non-randomized and observational designs from: 
http://guides.library.harvard.edu/c.php?g=309982&p=2079546  (Countway Library of Medicine, 31 Aug 2016). 
Date: 2016-08-31 
University Library Vrije Universiteit Amsterdam 
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Data search strategy for Ovid Medline®   
# Searches  






(Anticholesteremic or antihypercholesteremic or altocor or atorvastatin or baycol or bervastatin or canef or cerivastatin or compactin or 
cranoc or crestor or crilvastatin or dalvastatin or fluindostatin or fluvastatin or glenvastatin or hmg coa* or hydroxymethylglutaryl* or 
hypochol* or hypolipidemic* or lescol or lipitor or lipex or lipostat or livalo or locol or lovostatin or lochol or medostatin or mevacor or 
mevalotin or mevinacor or mevinolin or monacolin or pitava or pitavastatin or pravachol or pravasin or pravastatin or rosuvastatin or 
simvastatin or zocor or statin*).ab,kw,ti,nm. 
3 1 or 2  






(((muscl* or muscu*) adj3 (pain* or fatigue or intoler* or symptom*)) or (statin* adj3 (induc* or relat* or associ* or intoler* or symptom* or 
side effect* or side-effect* or adverse effect*)) or sams or sas or sinam or myopath* or myalg* or myosit* or necrot* or rhabdomyo*).ti,ab,kw. 
6 4 or 5  
7 3 and 6  
8 exp drug therapy/ Ma
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(((daily or everyday or quotidian or every other or every second or rotat* or alternat* or non daily or nondaily or non-daily or hebdomad* 
or weekly or intermit* or escalat* or build-up or intensif* or reduct* or puls*) adj3 (therap* or dos* or treatment or prescript*)) or reinitiation 
or challeng* or rechalleng* or re challeng* or monotherap*).ab,kw,ti. 
10 8 or 9  
11 7 and 10  




13 controlled clinical trial.pt. 
14 Randomi?ed.ab. 
15 placebo.ab. 





21 exp animals/ not humans.sh. 
22 20 not 21 















24 exp case control studies/ 
25 exp cohort studies/ 
26 Case control.tw. 
27 (cohort adj (study or studies)).tw. 
28 Cohort analy$.tw. 
29 (Follow up adj (study or studies)).tw. 
30 (observational adj (study or studies)).tw. 
31 Longitudinal.tw. 
32 Retrospective.tw. 
33 Cross sectional.tw. 
34 Cross-sectional studies/ 
35 or/23-34 
36 22 or 35  






Database search strategy for Cochrane library  
# Searches  
#1 (Anticholesteremic or antihypercholesteremic or altocor or atorvastatin or baycol or bervastatin or canef or cerivastatin or compactin 
or cranoc or crestor or crilvastatin or dalvastatin or fluindostatin or fluvastatin or glenvastatin or hmg coa* or hydroxymethylglutaryl* 
or hypochol* or hypolipidemic* or lescol or lipitor or lipex or lipostat or livalo or locol or lovostatin or lochol or medostatin or mevacor 
or mevalotin or mevinacor or mevinolin or monacolin or pitava or pitavastatin or pravachol or pravasin or pravastatin or rosuvastatin 






#2 (((muscl* OR muscu*) NEAR/3 (pain* OR fatigue OR intoler* OR symptom*)) OR ((statin* NEAR/3 (induc* OR relat* OR associ* 
OR intoler* OR symptom* OR “side effect“ OR side-effect* OR “adverse effect“)) OR sams OR sas OR sinam OR myopath* OR 






#3 #1 AND #2  
#4 
(((daily or everyday or quotidian or “every other“ or “every second“ or rotat* or alternat* or “non daily“ or nondaily or non-daily or 
hebdomad* or weekly or intermit* or escalat* or build-up or intensif* or reduct* or puls*) near/3 (therap* or dos* or treatment or 












#5 #1 AND #2 AND #4  
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Database search strategy for Scopus 
# Searches 
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TITLE-ABS-KEY ( anticholesteremic  OR  antihypercholesteremic  OR  altocor  OR  atorvastatin  OR  baycol  OR  bervastatin  OR  canef  
OR  cerivastatin  OR  compactin  OR  cranoc  OR  crestor  OR  crilvastatin  OR  dalvastatin  OR  fluindostatin  OR  fluvastatin  OR  
glenvastatin  OR  "hmg coa*"  OR  hydroxymethylglutaryl*  OR  hypochol*  OR  hypolipidemic*  OR  lescol  OR  lipitor  OR  lipex  OR  lipostat  
OR  livalo  OR  locol  OR  lovostatin  OR  lochol  OR  medostatin  OR  mevacor  OR  mevalotin  OR  mevinacor  OR  mevinolin  OR  
monacolin  OR  pitava  OR  pitavastatin  OR  pravachol  OR  pravasin  OR  pravastatin  OR  rosuvastatin  OR  simvastatin  OR  zocor  OR  
statin* )  AND  TITLE-ABS-KEY ( ( ( muscl*  OR  muscu* )  W/3  ( pain*  OR  fatigue  OR  intoler*  OR  symptom* ) )  OR  ( ( statin*  W/3  ( 
induc*  OR  relat*  OR  associ*  OR  intoler*  OR  symptom*  OR  "side effect*"  OR  side-effect*  OR  "adverse effect*" ) )  OR  sams  OR  
sas  OR  sinam  OR  myopath*  OR  myalg*  OR  myosit*  OR  necrot*  OR  rhabdomyo* ) )  AND  TITLE-ABS-KEY ( ( ( daily  OR  everyday  
OR  quotidian  OR  "every other"  OR  "every second"  OR  rotat*  OR  alternat*  OR  "non daily"  OR  nondaily  OR  non-daily  OR  hebdomad*  
OR  weekly  OR  intermit*  OR  escalat*  OR  build-up  OR  intensif*  OR  reduct*  OR  puls* )  W/3  ( therap*  OR  dos*  OR  treatment  OR  
prescript* ) )  OR  reinitiation  OR  challeng*  OR  rechalleng*  OR  "re challeng*"  OR  monotherap* )   
 15 




(atorvastatin OR fluvastatin OR pitavastatin OR pravastatin OR rosuvastatin OR simvastatin OR statin) AND (pain OR fatigue OR intolerance 
OR symptom OR side OR adverse OR myopathy OR myalgia OR myositis OR rhabdomyolysis OR muscular OR muscle) 
 16 
Datatbase search strategy for Proquest 
# Searches 
1 
AB,TI,IF(anticholesteremic OR antihypercholesteremic OR altocor OR atorvastatin OR baycol OR bervastatin OR canef OR cerivastatin OR 
compactin OR cranoc OR crestor OR crilvastatin OR dalvastatin OR fluindostatin OR fluvastatin OR glenvastatin OR “hmg coa*” OR 
hydroxymethylglutaryl* OR hypochol OR hypolipidemic OR lescol OR lipitor OR lipex OR lipostat OR livalo OR locol OR lovostatin OR lochol 
OR medostatin OR mevacor OR mevalotin OR mevinacor OR mevinolin OR monacolin OR pitava OR pitavastatin OR pivastatin OR 
pravachol OR pravasin OR pravastatin OR rosuvastatin OR simvastatin OR zocor OR statin*) AND AB,TI,IF(muscl* OR muscul* OR pain* 
OR fatigue OR intoler* OR symptom* OR SAMS OR SAS OR SINAM OR rhabdomyo* OR myosit* OR myopath* OR myalg* OR necrot*) 
 17 
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